Trials / Withdrawn
WithdrawnNCT04761848
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease: A Randomized, Controlled Trial.
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sadat City University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the current study is to evaluate the safety and efficay of cilostazol in treatment of patients with fatty liver disease. Several previous reports have shown that cilostazol ameliorates lipid imbalances in NAFLD. Cilostazol appeared to exert beneficial effects against NAFLD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol 50 MG | Cilostazol 50 MG tablet twice daily |
| DRUG | Placebo | Placebo tablet twice daily |
Timeline
- Start date
- 2021-02-16
- Primary completion
- 2024-10-31
- Completion
- 2024-12-31
- First posted
- 2021-02-21
- Last updated
- 2025-07-14
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04761848. Inclusion in this directory is not an endorsement.